TICKERNERD
Menu
ALLRALLRHealthcare · Biotechnology

ALLR Stock Forecast: Allarity Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.40
−2.10% on the day

The 1 Wall Street analysts covering Allarity Therapeutics, Inc. hold a median 12-month price target of $10 — +632.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$22.6M
Ticker Nerd rank
30 / 100
Median analyst target
$10
Analysts covering
1
Total return, dividends reinvested
1W
+2.2%
1M
+14.8%
YTD
+29.6%
1Y
+59.3%
From 52W high
−28.9%
From 52W low
+72.8%
$0.81
$1.97
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALLR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Allarity Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Momentum
67
Growth
63
Revisions
61
Quality
31
Volatility
31
Value
17
Accruals
16
Issuance
5

Size (88): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALLR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALLR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26ALLRHigh $10Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $10Median $10High $10

The green dot is the last close — the median target sits +632.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 June 2026Ascendiant CapitalMaintainsBuy—
8 June 2026Ascendiant CapitalMaintainsBuy$9.75 → $10
10 Apr 2026Ascendiant CapitalMaintainsBuy—
9 Dec 2025Ascendiant CapitalMaintainsBuy—
26 Sept 2025Ascendiant CapitalMaintainsBuy—
28 July 2025Ascendiant CapitalInitiatesBuy—
23 Aug 2022Ladenburg ThalmannDowngradeNeutral—
27 May 2022Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALLR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ALLR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Allarity Therapeutics, Inc. (ALLR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
65.5×

Cheaper than 5% of US stocks

Price / book
2.8×

Cheaper than 37% of US stocks

EV / EBITDA
−2.6×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
−92.2%

Higher than 2% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−3129.0%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−157.1%

Higher than 15% of US stocks

Return on assets
−25.3%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALLR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALLRAllarity Therapeutics, Inc.$22.6M
30
CELUCelularity, Inc.$22.7M
18
ABVCABVC BioPharma, Inc.$22.6M
14
MRKRMarker Therapeutics, Inc.$23.2M
59
CNSYCerenome, Inc.$23.3M
19
COCPCocrystal Pharma, Inc.$22.2M
56
JSPRJasper Therapeutics, Inc.$23.8M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Allarity Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALLR news & analysis

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

GlobeNewsWire · 14 Aug 2026positive

Allarity Therapeutics reported financial results for the second quarter ended June 30, 2026, and announced completion of its Phase 3-ready stenoparib manufacturing campaign. The company closed the quarter with $26.9 million in cash and restricted cash, was awarded a key U.S. patent protecting stenoparib exclusivity into 2042, reported AACR 2026 data linking higher stenoparib DRP scores with enhanced overall survival in advanced ovarian cancer, and obtained CLIA certification for its in-house laboratory to support U.S. clinical trials.

Why it matters — The results signal forward clinical and manufacturing progress for stenoparib, including patent protection into 2042, cash to sustain operations, and infrastructure to advance DRP-guided trials.

FAQ

Frequently asked questions about ALLR stock

What is the ALLR stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Allarity Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALLR stock a buy right now?

Of the 1 analysts covering Allarity Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Allarity Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALLR?

As at 22 Aug 2026, Allarity Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

Will ALLR stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +632.1% from the last close, and Ticker Nerd's factor model ranks Allarity Therapeutics, Inc. 30 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALLR stock forecast for 2030?

No analyst covering Allarity Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALLR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.

How has ALLR stock performed over the past year?

Allarity Therapeutics, Inc. returned +59.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Allarity Therapeutics, Inc. do?

Allarity Therapeutics is a clinical-stage precision medicine biopharmaceutical company dedicated to developing personalized cancer treatments for patients with difficult-to-treat malignancies. The company's lead program focuses on stenoparib, a novel orally available dual inhibitor of PARP1/2 and tankyrase 1/2, currently in Phase 2 clinical trials for advanced, platinum-resistant, and platinum-ineligible ovarian cancer.

What is the latest news on ALLR?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign". Allarity Therapeutics reported financial results for the second quarter ended June 30, 2026, and announced completion of its Phase 3-ready stenoparib manufacturing campaign. The company closed the quarter with $26.9 million in cash and restricted cash, was awarded a key U.S. patent protecting stenoparib exclusivity into 2042, reported AACR 2026 data linking higher stenoparib DRP scores with enhanced overall survival in advanced ovarian cancer, and obtained CLIA certification for its in-house laboratory to support U.S. clinical trials.

Company

About Allarity Therapeutics, Inc.

Allarity Therapeutics is a clinical-stage precision medicine biopharmaceutical company dedicated to developing personalized cancer treatments for patients with difficult-to-treat malignancies. The company's lead program focuses on stenoparib, a novel orally available dual inhibitor of PARP1/2 and tankyrase 1/2, currently in Phase 2 clinical trials for advanced, platinum-resistant, and platinum-ineligible ovarian cancer. The company received FDA Fast Track designation for stenoparib in ovarian cancer, enabling expedited development and review pathways. A cornerstone of Allarity's strategy is its proprietary Drug Response Predictor (DRP®) companion diagnostic platform, which uses gene expression signatures to identify patients most likely to benefit from specific therapies, enabling a precision medicine approach to oncology. Beyond ovarian cancer, the company is expanding stenoparib's clinical potential into other advanced cancers, including a Phase 2 trial in recurrent small cell lung cancer funded by the U.S. Veterans Administration. Headquartered in the United States with research operations in Denmark, Allarity also generates revenue through licensing and laboratory services agreements that provide external partners access to DRP® diagnostic algorithms and transcriptomic testing services.

CEO Mr. Thomas H. Jensen · 7 employees · United States · https://www.allarity.com